C
Chime Biologics
Providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing
About Chime Biologics
Chime Biologics is a top-tier Contract Development and Manufacturing Organization (CDMO), specializing in biologics. In simpler terms, it helps other companies develop and manufacture biological drugs, which are medicines made from living organisms or their components. Chime Biologics serves a global clientele, offering a comprehensive suite of services from early-stage cell line development to commercial-scale manufacturing.
The company operates in the biopharmaceutical market, a sector that focuses on creating drugs from biological sources. Chime Biologics' business model is centered around providing end-to-end solutions, meaning they assist clients throughout the entire drug development and manufacturing process. This model allows the company to generate revenue by charging for their specialized services.
Chime Biologics' operations are powered by a team of over 400 skilled employees and advanced technology from its Shanghai Innovation Center. The company has a proven track record in Investigational New Drug (IND) enabling through Biologics License Application (BLA) filing at its Wuhan campus. IND and BLA are stages in the drug approval process, indicating that Chime Biologics can support clients from early research stages to regulatory approval.
The company's success is driven by its commitment to reliable, compliant, flexible, and fast-paced services. It aims to make cutting-edge biologics affordable and accessible to patients worldwide, reflecting its commitment to global health. Chime Biologics also places a high value on business integrity, professional compliance, and the protection of clients' intellectual property rights.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2025 | — | — | Wuhan Optics Valley Financial Holding Group | ↗ |
| SERIES AOther financing | Feb 2023 | $17M | $625M | Panacea Venture | ↗ |
Growth signals
Latest recorded traffic for Chime Biologics is 2.9K monthly website visits, up 253.7% over the last three months. Chime Biologics's team grew 3.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chime Biologics in the Wuhan ecosystem
The Chime Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
VMS Group
Panacea Venture
Fidelity Investments- WGWuhan Optics Valley Financial Holding Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chime Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chime Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









